Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial
- PMID: 15855257
- DOI: 10.1210/jc.2005-0208
Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial
Abstract
Context: Treatment of GH-deficient adolescents in transition to adulthood remains challenging.
Objective: The objective was to assess the safety and efficacy of GH in GH-deficient adolescents in transition.
Patients: Fifty-eight GH-deficient adolescents (mean age, 15.8 +/- 1.8 yr; 33 males) at near completion of their linear growth participated in the study.
Intervention: Baseline studies were done while subjects were on GH. Subjects were retested (insulin-induced hypoglycemia) 4 wk after GH discontinuation and reclassified as persistently GH-deficient or controls (n = 18). GH-deficient subjects were randomized to GH (n = 25, approximately 20 microg/kg.d) or placebo (n = 15).
Setting: The multicenter study was conducted over a 2-yr period.
Main outcomes: Changes in body composition, bone mineral density (BMD), quality of life (QOL), cardiovascular and metabolic markers were measured.
Results: All groups had normal measures of lipid and carbohydrate metabolism, body composition, BMD, cardiac function, muscle strength, and QOL at baseline and after 2 yr. IGF-I concentrations decreased in all, but less so in the GH-group (P = 0.013). There was a greater increase in lean body mass (lesser adiposity) in the GH group than placebo at 12 months, but not at 24 months.
Conclusions: 1) GH-deficient patients properly treated in childhood can have normal BMD, body composition, cardiac function, muscle strength, carbohydrate and lipid metabolism, and QOL when reaching adult height; and 2) continuation of GH therapy for 2 yr did not change these measures as compared to placebo-treated or control subjects. GH-deficient adolescents in good metabolic status at the time of epiphyseal fusion may safely discontinue GH for at least 2 yr. Follow-up is needed to determine whether GH therapy is eventually warranted in subjects treated with GH during childhood.
Similar articles
-
The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.J Clin Endocrinol Metab. 1998 Jan;83(1):107-16. doi: 10.1210/jcem.83.1.4482. J Clin Endocrinol Metab. 1998. PMID: 9435425 Clinical Trial.
-
Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism.J Clin Endocrinol Metab. 2000 May;85(5):1912-7. doi: 10.1210/jcem.85.5.6613. J Clin Endocrinol Metab. 2000. PMID: 10843174 Clinical Trial.
-
Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group.J Clin Endocrinol Metab. 1997 Jan;82(1):82-8. doi: 10.1210/jcem.82.1.3643. J Clin Endocrinol Metab. 1997. PMID: 8989238 Clinical Trial.
-
Is GH therapy useful to preserve bone mass in transition-phase patients with GH deficiency?J Endocrinol Invest. 2005;28(10 Suppl):28-32. J Endocrinol Invest. 2005. PMID: 16550719 Review.
-
GH use in the transition of adolescence to adulthood.Endocr Dev. 2010;18:109-125. doi: 10.1159/000316131. Epub 2010 Jun 3. Endocr Dev. 2010. PMID: 20523021 Review.
Cited by
-
Growth hormone, insulin-like growth factors, and the skeleton.Endocr Rev. 2008 Aug;29(5):535-59. doi: 10.1210/er.2007-0036. Epub 2008 Apr 24. Endocr Rev. 2008. PMID: 18436706 Free PMC article. Review.
-
Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement.Endocr Connect. 2016 May;5(3):R1-R11. doi: 10.1530/EC-16-0024. Epub 2016 Apr 29. Endocr Connect. 2016. PMID: 27129699 Free PMC article. Review.
-
Approach to the Patient: Management of Pituitary Hormone Replacement Through Transition.J Clin Endocrinol Metab. 2022 Jun 16;107(7):2077-2091. doi: 10.1210/clinem/dgac129. J Clin Endocrinol Metab. 2022. PMID: 35262704 Free PMC article.
-
Mapping the journey of transition: a single-center study of 170 childhood-onset GH deficiency patients.Endocr Connect. 2021 Aug 13;10(8):935-946. doi: 10.1530/EC-21-0274. Endocr Connect. 2021. PMID: 34259648 Free PMC article.
-
Prospective Follow-up of Children with Idiopathic Growth Hormone Deficiency After Termination of Growth Hormone Treatment: Is There Really Need for Treatment at Transition to Adulthood?J Clin Res Pediatr Endocrinol. 2018 Jul 31;10(3):247-255. doi: 10.4274/jcrpe.0010. Epub 2018 Mar 19. J Clin Res Pediatr Endocrinol. 2018. PMID: 29553045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical